Sign in
ICPT Stock Price, Chart, Stats & News
Intercept Pharmaceuticals, Inc.
Save
794.69M
Market cap
–
Current P/E
–
Forward P/E
ICPT chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 99.66% |
Operating margin | -23.88% |
Pretax margin | -61.20% |
Net margin | 40.31% |
Effective tax rate | 165.87% |
ROA | 20.80% |
ROE | -253.45% |
D/E | 3.57x |
Interest coverage ratio | -3.19x |
ICPT valuation
P/E | – |
P/S | 2.78x |
P/B | 6.90x |
P/CF | -24.00x |
P/FCF | -29.06x |
P/OCF | -24.00x |
PEG | 0.06x |
EV multiple | -8.31x |
About
Intercept Pharmaceuticals, Inc. is a biopharmaceutical firm specializing in the advancement and market launch of therapies designed to treat progressive, non-viral liver conditions. Its operational reach spans the United States, Europe, and Canada. The company currently markets Ocaliva, a medication functioning as a farnesoid X receptor (FXR) agonist.
Similar securities
Based on sector and market capitalization
Report issue